Skip to main content

LIGHTPATH TECHNOLOGIES INC

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 13, 2025

LPTH$7.99-0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Unaudited Condensed Consolidated Statements of Cash Flows

LIGHTPATH TECHNOLOGIES, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)
Six Months Ended December 31,
20242023
Cash flows from operating activities:
Net loss$(4,234,742)$(3,056,039)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization1,893,6021,943,000
Interest from amortization of loan issuance costs120,833—
Loss on disposal of property and equipment78,437—
Stock-based compensation on stock options, RSUs & RSAs, net506,020551,853
Provision for credit losses—(2,236)
Change in operating lease assets and liabilities(57,653)80,355
Inventory write-offs to allowance135,62573,569
Deferred taxes(2,795)9,395
Changes in operating assets and liabilities:
Trade accounts receivable(350,703)1,717,283
Other current assets41,286(191,381)
Inventories(13,005)54,461
Prepaid expenses and deposits(123,598)94,619
Accounts payable and accrued liabilities(430,923)(424,310)
Net cash (used in) provided by operating activities(2,437,616)850,569
Cash flows from investing activities:
Purchase of property and equipment(160,155)(1,484,401)
Proceeds from sale of equipment10,648—
Proceeds from sale-leaseback of equipment—364,710
Acquisition of Visimid, net of cash acquired—(722,141)
Net cash used in investing activities(149,507)(1,841,832)
Cash flows from financing activities:
Proceeds from sale of common stock from Employee Stock Purchase Plan10,37219,719
Deferred payment for acquisition of Visimid(125,000)—
Loan issuance costs(300,000)—
Borrowings on loans payable3,000,000142,853
Payments on loans payable(106,486)(407,510)
Repayment of finance lease obligations(89,705)(58,785)
Net cash provided by (used in) financing activities2,389,181(303,723)
Effect of exchange rate on cash and cash equivalents(81,260)32,698
Change in cash, cash equivalents and restricted cash(279,202)(1,262,288)
Cash, cash equivalents and restricted cash, beginning of period3,480,2687,144,490
Cash, cash equivalents and restricted cash, end of period$3,201,066$5,882,202
Supplemental disclosure of cash flow information:
Interest paid in cash$40,838$110,774
Income taxes paid$61,427$114,953
Supplemental disclosure of non-cash investing & financing activities:
Purchase of equipment through finance lease arrangements$93,048$61,654
Issuance of common stock for acquisition of Visimid$321,358$150,000
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.